A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment
The purpose of this study is to evaluate the safety and efficacy of ofatumumab and
bendamustine combination therapy in patients with indolent B-cell NHL that did not respond
to rituximab or a rituximab-containing regimen during or within 6 months of the last
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society